Health Care · Pharmaceutical Preparations

BBIO BridgeBio Pharma, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1743881114 filings
Russell 2000

BBIO at a glance

BridgeBio Pharma, Inc. (BBIO, SEC CIK 1743881) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Pharma, Inc. (BBIO) reported revenue of $502.1 million (up 126.3% from FY2024) and a net loss of $724.9 million. Diluted EPS was -$3.78.
  • As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding BridgeBio Pharma, Inc. (BBIO) shares worth $5.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Kumar Neil on November 19, 2026 of 8,500 shares at $78.35 per share.
  • In the last 90 days, BBIO insiders reported 0 open-market purchases ($0) and 9 open-market sales ($5.1M) on Form 4, a net sale of $5.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$502.1M
+126.3% vs prior year
Insiders · 90 days
0 buys · 9 sells
Net −$5.1M
13F holders
35 funds
$5.0B · −3 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Biopharmaceutical development and commercialization with focus on genetic diseases and novel therapies
  • New emphasis on commercialization with FDA approval and US launch of Attruby (net product revenue $362.4M in 2025)
  • Strategic shift: Exclusive EU license of acoramidis to Bayer and sale of royalty rights generating $300M upfront cash
  • Increased SG&A expenses by $242.3M in 2025 supporting commercial launch of Attruby; R&D expenses decreased $54.5M due to program reprioritization
  • Raised $619.3M net from 0.75% convertible notes due 2033 in 2026, used partly for common stock repurchase and refinancing debt

Risk Factors

  • Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience
  • Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership
  • Board of Directors receives periodic updates on cybersecurity risks and risk management from executive leadership
  • Data Privacy and Security Committee meets quarterly to discuss cybersecurity risk management and reports to Audit Committee

Management Discussion & Analysis

  • No profitability or margin percentages reported
  • No cash flow, buybacks, dividends, or capex figures stated
  • Forward-looking risks and uncertainties highlighted, no specific guidance or outlook provided

AI summary of the BBIO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New regulatory risk: CMS finalized GLOBE on October 2, 2026, requiring internationally benchmarked Medicare Part B rebates beginning January 1, 2027
  • Most material update: FDA scrutiny of promotional practices, including an untitled letter concerning Attruby’s DTC broadcast advertisement
  • Compliance exposure: Medicaid, 340B and VA pricing errors could trigger refunds, civil penalties, or program termination
  • Commercial risk: Attruby faces competition as it is not the first ATTR-CM treatment on the market
  • Supply risk: Attruby and Beyonttra rely on one primary drug-product supplier, despite a secondary supplier agreement

Management Discussion & Analysis

  • Revenue $353.2M, up $232.5M YoY, driven by Attruby product revenue $253.3M vs $108.1M
  • Operating margin negative 3.3% vs negative 120.3% YoY, based on operating loss $11.6M vs $145.2M
  • Best line: Attruby revenue up $145.3M; worst line: license and services revenue up $71.0M, boosted by a $75.0M Bayer milestone
  • Cash, equivalents and securities $1.5B vs $587.5M; operating cash outflow $312.6M for nine months
  • Near-term losses expected for several years; liquidity projected for at least 12 months, with headwinds from commercialization, inflation and supply chain issues

AI summary of the BBIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $353.2M, including Attruby product revenue $253.2M, up $145.2M year over year
  • Attruby adoption accelerating in treatment-naïve patients, strengthening commercial momentum in ATTR-CM

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026, covering financial performance and recent business updates
  • Exhibit 99.1 contains the full earnings release, the primary source for detailed results and guidance
Filed Oct 13, 2026Full analysis →

Item 8.01: Other Events

  • FDA accepted BridgeBio’s NDA for oral infigratinib in children with achondroplasia
  • Priority review accelerates FDA evaluation and may shorten the path to potential approval

Item EX-99.1: Item EX-99.1

  • FDA accepted oral infigratinib NDA with Priority Review, setting a February 4, 2027 PDUFA target date
  • Potential first approved oral achondroplasia therapy, supporting BridgeBio’s planned U.S. launch upon approval
Filed Aug 31, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Voluntary U.S. agreement expands Medicaid access to Attruby through the GENEROUS Model
  • Attruby remains available through Medicare Part D without future pricing mandates

Item 8.01: Other Events

  • Agreement with U.S. government targets affordability and access for BridgeBio’s future medicines
  • Pricing commitment expected to exclude medicines approved exclusively for orphan indications

AI summaries of BBIO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BBIO

Don't miss the next BBIO filing

  • Alerts as it files. A push when BBIO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BBIO, by share count.
  • Ask anything. An AI agent that reads every BBIO filing and answers with sources.

BBIO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Kumar NeilSellNov 19, 2026$78.35
Kumar NeilSellNov 19, 2026$79.29
Kumar NeilSellNov 18, 2026$77.83
Kumar NeilSellNov 18, 2026$77.83
Kumar NeilSellNov 18, 2026$76.99
Kumar NeilSellNov 18, 2026$76.99
Kumar NeilFNov 16, 2026$77.36
Kumar NeilMNov 16, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$221.9M$502.1M
Operating Income-$607.4M-$593.0M-$523.4M
Net Income-$643.2M-$535.8M-$724.9M
Op. Margin--267.2%-104.2%
Net Margin--241.4%-144.4%
Balance Sheet
Total Assets$546.4M$919.3M$936.0M
Equity--$1.5B-$2.1B
ROE-36.5%34.7%
Per Share
EPS$-3.95$-2.88$-3.78
Cash Flow
Operating CF--$520.7M-$445.9M
CapEx-$933K$1.1M

Source: XBRL data in BridgeBio Pharma, Inc. (BBIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BBIO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BBIO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202635$4.97B
Q2 202638$5.74B
Q1 202637$6.17B
Q4 202529$6.00B
Q3 202531$4.07B
Q2 202530$3.43B
Q1 202526$2.13B
Q4 202421$1.51B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 247 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BBIO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 3, 2026--
10-QOct 29, 2026Analysis
8-KOct 29, 2026Analysis-
8-KOct 13, 2026Analysis-
4Sep 21, 2026--
8-KAug 31, 2026Analysis-
4Aug 20, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
8-KAug 17, 2026Analysis-
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
4Aug 3, 2026--
8-KJul 22, 2026Analysis-
4Jul 13, 2026--
4Jul 13, 2026--
8-KJul 2, 2026Analysis-
8-KJun 26, 2026Analysis-
4Jun 24, 2026--
4Jun 24, 2026--

Related Health Care companies

All Health Care →

BBIO SEC filings: frequently asked questions

Are BBIO insiders buying or selling?

In the last 90 days, BridgeBio Pharma, Inc. (BBIO) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $5.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BBIO stock?

As of September 30, 2026, the largest BridgeBio Pharma, Inc. (BBIO) holders among the 13F filers tracked by SignalX were BlackRock ($683.6 million), Viking Global Investors ($644.3 million), Vanguard Capital Management LLC ($520.7 million), Vanguard Portfolio Management LLC ($492.5 million), State Street Corp ($327.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BBIO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Pharma, Inc. (BBIO) reported revenue of $502.1 million (up 126.3% from FY2024) and a net loss of $724.9 million. Diluted EPS was -$3.78. The figures come from the XBRL data in the 10-K.

What are the main risks in BBIO's latest 10-K?

In the 10-K filed February 24, 2026, BridgeBio Pharma, Inc. (BBIO) flagged: Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience. Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership. (AI summary of the Risk Factors section.)

What did BBIO report in its latest 8-K?

BridgeBio Pharma, Inc. (BBIO) filed an 8-K on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $353.2M, including Attruby product revenue $253.2M, up $145.2M year over year.

What are the latest BBIO SEC filings?

BridgeBio Pharma, Inc. (BBIO) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 20, 2026.

What is BBIO's SEC CIK number?

BridgeBio Pharma, Inc. (BBIO)'s SEC Central Index Key (CIK) is 1743881. EDGAR lists every BBIO filing under that number.

Ask anything about BBIO

The research agent reads BBIO's filings, financials, insider trades and 13F holders, then answers with sources.